Perrigo Company plc, received US Food and Drug Administration (FDA) approval for the generic version of Valeant Pharmaceutical International Inc's BenzaClin topical gel.
Perrigo's product is therapeutically equivalent to BenzaClin gel 1%/5% and it will produce the same clinical effect and safety profile as BenzaClin gel 1%/5% when used under the conditions specified in the label.
BenzaClin topical gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending July 2015 were $231 million.
Subscribe to PharmaTutor News Alerts by Email >>
